DSpace DSpace Softwareについて

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2016年度 >

このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/10564/3314

タイトル: Feasibility and efficacy of definitive radiotherapy with 66 GY and concurrent carboplatin-paclitaxel chemotherapy for stage Ⅲ non-small cell lung cancer.
その他のタイトル: Ⅲ期非小細胞肺癌に対するカルボプラチン・パクリタキセル同時併用66Gy放射線治療の安全性と有効性について
著者: Inoue, Kazuya
Hontsu, Shigeto
Miura, Sachiko
Asakawa, Isao
Tamamoto, Tetsuro
Yoshimine, Tadashi
Kimura, Hiroshi
Hasegawa, Masatoshi
キーワード: Non-small cell lung cancer
Concurrent chemoradiotherapy
Carboplatin-paclitaxel chemotherapy
発行日: 2017年4月
出版者: 奈良医学会
引用: Journal of Nara Medical Association Vol.68 No.1-2 掲載予定 (2017.04)
抄録: Purpose/Objectives: This study was conducted to assess the feasibility and efficacy of definitive radiotherapy (RT) with a total dose of 66Gy and concurrent carboplatin-paclitaxel chemotherapy for patients (pts) with stage Ⅲ non-small cell lung cancer. Materials/Methods: Between April 2007 and December 2013, 99 pts with non-small cell lung cancer were treated by RT with concurrent carboplatin-paclitaxel chemotherapy in our hospital. Sixty-eight of them received RT with a total dose of 66Gy. We analyzed 46 Stage Ⅲ pts who had been treated with RT using three-dimensional radiotherapy treatment planning. The prophylactic mediastinal lymph nodes were included in the clinical target volume of RT. The survival rate after the beginning of RT was estimated using the Kaplan-Meier method. We estimated the cumulative local failure and distant metastasis rates with the Fine-Gray method. Adverse events were evaluated according to the CTCAE (v.4.0). Results: The median age of the pts was 70.9 (52.8-78.7) years old (y.o.). The performance status (PS) of each pt was fairly good (ECOG PS 0: 25, PS 1: 20, PS3:1), and clinical stages (UICC 7th) consisted of twenty-nine ⅢA and seventeen ⅢB. Diagnoses were pathologically confirmed in 32 pts. The median follow-up period was 35.7 (2.0-82.2) months among all pts, and 55.9 (40.1-82.2) months among survivors. The 3- and 5-year Kaplan-Meier overall survival rates were 52.2 and 34.0%, respectively, and the median survival time was 36.6 months. The 3- and 5-year Kaplan-Meier progression-free survival rates were 29.1 and 21.9%, respectively, and the median progression-free survival time was 9.9 months. The 5-year local failure rate was 37.6%, and the 5-year distant metastasis rate was 49.7%. Sixteen (34.8%) pts required steroid administration because of radiation pneumonitis (CTCAE Grade 2 or higher) and two of them died (Grade 5). No other severe non-hematologic toxicity (Grade 3 or higher) was observed. Conclusion: These results suggest that definitive RT with a total dose of 66Gy and concurrent carboplatin-paclitaxel chemotherapy is feasible and may be promising for pts with Stage Ⅲ non-small cell lung cancer.
内容記述: 博士(医学)・甲第663号・平成29年3月15日
URI: http://hdl.handle.net/10564/3314
ISSN: 13450069
学位授与番号: 24601A663
学位授与年月日: 2017-03-15
学位名: 博士(医学)
学位授与機関: 奈良県立医科大学


ファイル 記述 サイズフォーマット
01 甲663本文の要旨.pdf甲663本文の要旨252.04 kBAdobe PDF見る/開く
02 甲663審査要旨.pdf甲663審査要旨437.6 kBAdobe PDF見る/開く
03 甲663本文.pdf甲663本文1.4 MBAdobe PDF見る/開く



Valid XHTML 1.0! Powered by DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - ご意見をお寄せください